Tejara Capital’s Ocular Therapeutix OCUL Stock Holding History

Tejara Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-72,457	Closed	-$382K	–	91
2023 Q1	$382K	Sell	72,457 -30,000	-29%	-$142K	0.2%	64
2022 Q4	$288K	Buy	+102,457	New	+$339K	0.17%	82

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tejara Capital's OCUL Position: Q2 2023 in Review

Tejara Capital sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 72,457 shares — an estimated $382K sold.

Tejara Capital first reported a position in OCUL in Q4 2022 and held it in 2 quarters. The position peaked at $382K in Q1 2023. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

Tejara Capital reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
Tejara Capital sold 72,457 Ocular Therapeutix shares in Q2 2023, an estimated $382K.
Tejara Capital first reported a position in Ocular Therapeutix in Q4 2022 and held it in 2 quarters.
Tejara Capital's Ocular Therapeutix position peaked at $382K in Q1 2023.
135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on Tejara Capital's 13F filing for Q2 2023, filed 11 Aug 2023.